Nephraegis Therapeutics is focused on developing innovative solutions to prevent Acute Kidney Injury (AKI), a condition characterized by a sudden loss of kidney function that can occur after various surgical procedures. The company is addressing a significant unmet medical need, as current treatments for AKI are limited to supportive care, with no approved drugs available. Their lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) that has shown promising efficacy and safety in preclinical models. EETs are known to play a crucial role in regulating renal and vascular functions, making NPH-022 a potential breakthrough therapy for preventing AKI and improving patient outcomes.

The economic burden of AKI is substantial, with direct costs in the United States estimated at $24 billion annually, not including the expenses associated with dialysis and transplants for patients who progress to end-stage renal disease (ESRD). Nephraegis Therapeutics aims to target high-risk patients, a market that exceeds $8 billion annually, by leveraging their proprietary drug candidates. The company’s commitment to addressing AKI aligns with the priorities of major advocacy groups, highlighting the urgent need for effective treatments that can enhance the quality of life for patients at risk of kidney failure.

United States

Nephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI).


Nephraegis Therapeutics

Company Details